As Drug Shortages Linger, Attention Turns to TPN Crisis
This article was originally published in The Gold Sheet
The good news is that the number of new drug shortages went down in 2012; the bad news is that the total number of drugs in active shortages is increasing while growing capacity problems are being reported – and shortages of injectable nutrition drugs are especially acute. An FDA economist proposes that rewarding manufacturers for quality may help to alleviate the shortage crisis.
You may also be interested in...
How FDA, health care providers, and Pfizer and other drug makers are responding to a shortage of emergency medicines from the fragile, overstressed US sterile injectables sector.
While COVID-19 continues to wreak havoc on FDA's ability to perform onsite preapproval inspections, new guidance offers some clarity, but the news isn't great for ANDA holders.
The WHO proposes to revise 2011 guidance on technology transfers to ease the hand-off of COVID-19 drugs and vaccines from research and development facilities to commercial sites.